电针干预特发性面神经麻痹急性期的疗效评价与机制研究:随机对照试验研究方案
主要结局为基线至发病第30天Sunnybrook面神经评分系统(SFGS)的变化,次要结局包括H-B分级、NRS、FDI、表面肌电图和MRI,旨在评价急性期电针联合泼尼松的临床疗效、预后及安全性,并通过sEMG和MRI探讨机制。
要点
- 急性期在口服泼尼松片基础上加用电针,与单纯口服泼尼松片进行比较。
- 主要结局为基线至发病第30天SFGS评分变化,次要结局含H-B、NRS、FDI、sEMG和MRI。
- 试验组急性期至少治疗6次,两组恢复期均治疗9次,治疗后随访15天。
核心结论
- 本试验旨在比较急性期电针联合口服泼尼松片与单纯口服泼尼松片在IFP中的疗效与预后差异。
- 研究将通过sEMG客观观察面部表情肌功能恢复,并通过MRI动态观察急性期面神经形态学改变以揭示机制。
研究设计与样本
- 治疗分急性期和恢复期两个阶段,对照组急性期口服泼尼松片,试验组在此基础上同步加用电针治疗。
- 两组恢复期均停用泼尼松片并转为电针治疗,试验组急性期至少治疗6次,两组恢复期均治疗9次,治疗后随访15天。
关键数值与推荐
- 主要结局为基线至发病第30天SFGS评分的变化。
- 次要结局包括H-B分级、NRS评分、FDI(含FDIP和FDIS)、sEMG和MRI。
- 不良事件将被记录用于安全性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies had already reported the efficacy of electroacupuncture treatment for idiopathic facial nerve palsy (IFP) in a recovery phase; however, the initial use of electroacupuncture in the acute phase remains controversial. Hence, in the present study, we will add electroacupuncture intervention based on oral prednisone tablets in the acute phase of IFP and compare the clinical effects with simple oral prednisone tablets. Besides, the prognosis and safety will be evaluated. The present study aims to evaluate the clinical efficacy, prognosis, and safety of electroacupuncture combined with oral prednisone tablets in the acute phase of IFP, using surface electromyography (sEMG) to objectively observe the recovery of facial expression muscle function. In addition, the morphological changes of the facial nerve were observed dynamically by magnetic resonance imaging (MRI) in the acute phase to reveal the effect mechanism of this therapy. METHODS: Randomized controlled trials will be conducted in the first teaching hospital of Tianjin University of Traditional Chinese Medicine in China from September 2020 to April 2021. The treatment will be carried out in two phases, including the acute phase and the recovery phase. Eighty IFP patients will be recruited and randomized into two groups with a 1:1 ratio. Subjects in the acute phases of the control group will be given oral prednisone tablets, based on the control group, and subjects of the experimental group will be given electroacupuncture therapy simultaneously in the acute phase. Both groups will be stopped taking prednisone tablets and turn to electroacupuncture therapy in a recovery phase. Patients in the experimental group will receive treatment at least 6 times in the acute phase and both groups will receive treatment 9 times in the recovery phase, and there will be a follow-up period of 15 days after the treatment. The primary outcome is supposed to be related to the changes observed in the Sunnybrook (Toronto) Facial Grading System (SFGS) on the baseline and day 30 after the onset. Secondary outcome measures will include House-Brackmann Facial Nerve Grading System (H-B), measurement of Numerical Rating Scale (NRS), Facial Disability Index scale (FDI, including physical function subscore, FDIP, and social functioning and well-being subscore, FDIS), surface electromyogram (sEMG), and magnetic resonance imaging (MRI). Adverse events will be recorded for safety assessment. DISCUSSION: The results of this trial will allow the present study to compare the difference in efficacy and prognosis between the strategy of combined electroacupuncture in the acute phase and only oral prednisone tablets. The findings from this trial will be published in peer-reviewed journals. TRIAL REGISTRATION: CHICTR ChiCTR2000038472 . Registered on 23 September 2020.
引用
- Qin Y, Yang L, Zhang M, et al. Efficacy evaluation and mechanism study of electroacupuncture intervention in acute phase of IFP: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34583756. doi:10.1186/s13063-021-05632-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。